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Background: Urine specimens are commonly used in biomarker research. Urinary creatinine (UCr) is often used to adjust for urine analyte
concentration. We aim to explore the applicability of UCr as a normalization method in a cystic fibrosis (CF) population during hospitalization.
Methods: Multiple spot urine samples were collected from CF patients hospitalized for a pulmonary exacerbation. Single spot specimens were
obtained from asthmatics and healthy children for comparison. The assumptions and implications from the use of UCr as a normalization factor for
urinary desmosine measurements were investigated.
Results: UCr differed significantly across disease groups and decreased significantly over time in the CF population. Differing results were
obtained when contrasting normalization by UCr with specific gravity.
Conclusions: UCr levels are not completely attributable to simply variations in urine concentration. Analysis of urinary biomarker measurements
should be initiated with an understanding of the relative effects of the normalization process on the results.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Urinary biomarkers; Urinary creatinine; Cystic fibrosis; Normalization factor; Specific gravity; Pulmonary exacerbation1. Introduction
Urine specimens are commonly employed in cystic fibrosis
(CF) biomarker research for the measurement of infectious and
inflammatory mediators. Urine is an ideal specimen, given it can
be collected non-invasively, is usually plentiful and poses
minimal risk. Spot urine samples are preferred to 24-hour
collections for feasibility and to avoid improper and incomplete☆ Data from this manuscript has previously been presented in poster form at
the North American Cystic Fibrosis Conference, Orlando, FL; October 2008.
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doi:10.1016/j.jcf.2010.02.00424-hour collection. The major disadvantage of spot urine samples
is the variation in dilution effects, sample volume and the rate of
urine production [1]. In an attempt to adjust for this variation,
urinary creatinine (UCr) concentration is most commonly used in
a ratio format to normalize analyte quantification for specimen
concentration. The normalization process involves dividing the
concentration of the analyte of interest by the UCr concentration
obtained in the same urine sample, with the result reported as the
concentration of target analyte per milligram of creatinine.
Creatinine is a waste product of muscle metabolism and is
excreted in urine at a relatively constant rate through glomerular
filtration [2,3]. It is the relative stability within an individual that
makes it an attractive approach for normalization of analyte
concentrations. However, the rate of creatinine excretion has been
shown to vary across different patient demographics, introducingd by Elsevier B.V. All rights reserved.
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UCr for normalization [4]. Creatinine excretion has been
documented to increase throughout the growth period, peaking
at 20–30 years of age, and decreasing thereafter, reflecting the
changes in body muscle tissue mass [1]. Furthermore, UCr
concentrations are known to vary by gender, ethnicity and dietary
protein levels [5–8]. Creatinine adjustment is thought to work
best when the renal elimination mechanism of the analyte is
similar to the renal elimination mechanism of creatinine [2,4,9].
Patients with CF may have reduced creatinine levels or
irregular urinary excretion of creatinine due to several biological
factors, including reduced muscle mass related to nutritional
difficulties, the presence of a hyper-catabolic state from chronic
systemic inflammation, limited exercise capacity, and frequent
pulmonary exacerbations or illness [10–12]. CF patientsmay also
have renal impairment (decreased glomerular filtration rate),
potentially related to cumulative aminoglycoside use, even in the
presence of a normal blood urea and serum creatinine [10–13].
Given the potential variability in excretion and quantity, UCrmay
not be an appropriate normalizing factor to use for urinary
biomarker quantification in a CF population during illness or
when making comparisons with this population.
An alternative method for normalization is specific gravity
(SG), which is defined as the ratio of the density of a urine
specimen to the density of water. SG values increase with solute
concentration. Our aim was to investigate the effect of using
UCr as a normalization factor for spot urine samples in
hospitalized CF patients and for comparison with samples
obtained from patients with asthma and from healthy controls
without lung disease. To provide further evaluation of the
appropriate measure of urinary concentration, SG values will
also be examined. This investigation is necessary if accurate
inferences from urinary biomarker studies within the hospital-
ized CF population are to be achieved.
2. Methods
2.1. Study population
Fifty-three patients with a confirmed diagnosis of CF [14]
resulting in 63 hospital admissions were enrolled into our study of
urinary desmosine concentration during pulmonary exacerbation.
Patients were identified upon admission to the inpatient unit at
The Children's Hospital, Denver and were required to have ≥2
intravenous (IV) antibiotics administered for treatment of their
exacerbation to qualify for the study. Spot urine samples from 15
control children without lung disease and 50 stable asthmatic
outpatients were collected for comparison. All study protocols
were approved by the Colorado Multiple Institutional Review
Board and/or the National Jewish Research Hospital Institutional
Review Board. Informed consent and/or assent were obtained
from each of the subjects and/or their parents or guardians.
2.2. Study design
This was a prospective cohort study of CF patients
hospitalized for a pulmonary exacerbation. All patients receivedstandard-of-care therapies including airway clearance, nutri-
tional support and IV antibiotics. Standard doses of IV
antibiotics were used and blood levels monitored where
appropriate. An attempt to collect three urine samples from
each CF patient was made, with the first targeted around 72 h
from admission, the second an interim sample and a third, final
sample prior to hospital discharge. Urine samples were
centrifuged before freezing at −80 °C prior to shipment for
analysis. Healthy control and asthmatic children provided a




The analyte of interest for this study was desmosine, a
breakdown product of elastin and a major component of the
extracellular matrix of the lung. Urinary desmosine concentration
is thought to be reflective of lung injury [15]. The analyte
concentration was measured in all urine samples using a
radioimmunoassay (RIA) performed by Elastin Products, Inc.
(Owensville, MO, USA) [16–19]. UCr was also measured by
Elastin Products, Inc. using creatinine assay reagents from Sigma
Diagnostics (St. Louis, MO, USA). SG was measured in the CF
and control urine samples by a total solids refractometer at The
Children's Hospital, Denver (American Optical Corp., Scientific
Instrument Div., Buffalo, NY).
3.2. Statistical analyses
The UCr and analyte values were log (base 10) transformed.
Two-sample t-tests and chi-squared tests were used to compare
means and percentages, respectively, across disease groups. A
simple linear regression was used to test the association across
disease groups, age and gender. To estimate the change over
time within the CF population, a repeated measures means
model with a random subject effect was fit. Normalization of the
analyte concentrations was performed using linear regression
models where the adjustment for UCr or SG was achieved by
including them as covariates, as this is the preferred method of
adjustment [20–23]. After graphical inspection of the associa-
tions between the analyte and UCr and SG, a quadratic
association was assumed for UCr and a linear association was
assumed for SG. The least square means from these models
were used to assess statistical significance across disease groups
and over time in the CF patients. All analyses were performed




Hospitalized CF patients were significantly younger
(pb0.01) than the asthma group and slightly older than the
healthy control group (Table 1). The gender distributions did
Table 1









Age a 15 (0.9) 20 (0.3) 13 (1.6)
Female 39 (62%) 26 (52%) 12 (80%)
a Indicates that p-value comparing corresponding mean or percents between
hospitalized CF patients and asthma patients was less than 0.05.
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noticeably more females in the control group compared to the
other two disease groups (Table 1). Fifty-eight (89%) of
hospital admissions for CF pulmonary exacerbation involved
the use of intravenous aminoglycosides and the mean FEV1
percent predicted in the CF population upon admission was
66% (standard error (SE): 3.9%).
4.2. Urinary analyses
The log transformed urinary creatinine values in the CF
group (mean (SE): 0.25 (0.01)) were significantly lower
compared to both the healthy controls and the asthma group,
with means and (SEs) of 0.34 (0.04) and 0.40 (0.14),
respectively (both p-valuesb0.01). These distributions are
displayed in Fig. 1. In addition to the differences across disease
groups, UCr levels decreased significantly over time during
hospitalization in the CF patients (p=0.04). To provide further
evaluation, SG was also assessed in the CF and healthy control
samples. No significant differences in SG were observed
between the CF and healthy controls (means and (SEs): 1.020
(0.001) versus 1.017 (0.002)). Table 2 provides the least square
means and 95% confidence intervals (CI) for UCr and SG at the
three time points. UCr in the CF population decreased by 23.1%
between measurements collected from admission to discharge
(pb0.01). There was no corresponding decrease observed over
time in SG.
The differences in log UCr across the three disease groups
remain significant (pb0.01) even after adjusting for the
disparities in the age and gender distributions. The inclusion
of these three factors in a simple linear regression explainedFig. 1. Boxplots displaying the distribution of urinary creatinine in each group.
Urinary creatinine is significantly lower in the CF pulmonary exacerbation
group compared to the other populations.26.6% of the variability observed in UCr values. There was an
increase in UCr values with increasing age (parameter estimate
(SE)=0.003 (0.002)) and females had lower UCr values on
average (parameter estimate (SE)=−0.03 (0.02)) compared to
males. There was no discernable difference in the UCr levels in
the CF group between those given aminoglycosides versus
those that were not at any of the three time points nor in the
differences between admission and discharge. In a separate
regression, which excluded the asthma group, SG measure-
ments explained 29.0% of the UCr variability. The associations
between UCr and SG are visibly different, although not
significantly, between the CF patients and the healthy control
group (Fig. 2).
To investigate the effects of UCr normalization, the analyte
hypotheses of interest were tested by calculating the differences
in least square means from several mixed models using
variations of normalization factors. The results for three
comparisons of interest are displayed in Table 3 and consist
of contrasts; between CF and healthy controls, between CF and
asthma patients and over time in the CF patients. There is a
significant elevation in the analyte levels in the CF urine
samples compared to both the healthy controls and the asthma
patients after adjusting for UCr. This difference is less
pronounced, however, when adjustment for SG or no
adjustment is made. A significant decrease in the analyte levels
over time in the CF patients is observed when adjustment for SG
or no adjustment is made, whereas with an UCr adjustment, the
decrease is only slightly detectable. In addition to investigating
the normalization factors separately, they were also considered
jointly, when both UCr and SG were adjusted for as covariates
in the model, both contributed significantly to the determination
of the analyte levels. Moreover, the analyte levels were
significantly elevated in the CF group compared to controls
and the decrease over time was more pronounced than when
UCr was considered alone.
5. Discussion
Creatinine is thought to be excreted at a normal and constant
rate in healthy individuals and it is this assumption that makes
UCr an appealing factor for normalization [2,3]. This study
sought to explore the use of urinary creatinine as an acceptable
method of specimen normalization for spot urine samples
collected during a CF pulmonary exacerbation. We showed that
UCr levels varied significantly across disease groups and over
time in hospitalized CF patients. These differences could not be
fully explained by variations in age and gender distributionsTable 2











Log CR 0.26 (0.24, 0.29) 0.22 (0.19, 0.24) 0.20 (0.17, 0.23)
Fig. 2. Relationship between UCr and SG in CF patients (black stars) and
healthy controls (grey dots). The association in the CF patients is shifted
downwards compared to the associations in the healthy controls.
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measured by SG. Most importantly, depending on the
normalization method used, we obtained varying results for
our comparisons of interest. In summation, the SG adjustment
yielded similar results to those obtained with no adjustment and
the UCr adjustment differed widely from both SG and no
adjustment. This is likely due to the fact that UCr levels cannot
be completely attributable to variations in urine concentration.
Adjusting for urine concentration is similar to quantifying a
source of random noise across all samples, whereas the UCr
values are likely adjusting for other factors that might be
specific to a group of subjects, such as renal function or reduced
muscle mass. It remains unclear, however, whether it is
necessary or appropriate to adjust for these extraneous factors.
Heavner et al [2] showed that creatinine regression adjusted
biomarker values correlated well with the 24-hour urinary
biomarker values. This correlation, however, indicates that the
paired UCr adjustment can be used to approximate the 24-hour
value relatively well within an individual but does not
necessarily mean that the UCr adjusted value can be used to
accurately compare concentrations across individuals. UCr has
similarly been found to be a problematic normalization factor
both within certain populations [2,4,24] and when used to
compare biomarker measurements across different demograph-
ic groups with known variability in UCr [2–4,25]. Previous
studies have likewise shown decreased UCr levels from 24-hour
urine samples in the stable CF population compared to age-
matched control patients [25,26] as well as decreased renalTable 3
Comparison of analyte results across normalization methods.
Differences in least square means
(95% CI)
Increase in CF patients compared to
healthy controls
Unadjusted analyte log(pmol/ml) 0.12 (−0.13, 0.37)
UCr regression adjusted analyte log(pmol/ml) 0.43 (0.30, 0.56)
SG regression adjusted analyte log(pmol/ml) 0.05 (−0.08, 0.18)
UCr and SG regression adjusted analyte
log(pmol/ml)
0.21 (0.08, 0.34)
Values in bold indicate differences with p-valuesb0.05.function with aminoglycoside use [10–13,27,28]. This, in
addition to the association with SG observed here, suggests that
the lower UCr values in the hospitalized CF population are
likely the result of lower creatinine production and impaired
renal function rather than lower specimen concentration. Unless
it is known that the creatinine level is directly relational to the
analyte level (i.e., as in the case where the analyte is cleared
similarly to creatinine, in which case renal function becomes
relevant), these differences will bias the results when comparing
UDes across groups while using UCr as a normalization factor
[5].
This study focused on the implications of the choice of
normalization, specifically, within a hospitalized CF popula-
tion. It is not uncommon for urinary analyte concentrations to be
normalized to urinary creatinine concentrations in a CF
population [19,26,29,30]. However, special consideration is
warranted to determine the appropriate correction factor and
whether corrections are needed for features such as renal
function or differences in patient demographics. Analysis of
urinary measurements should be initiated with a conscientious
understanding of the relative effects of the normalization
process on the results. The future of urinary biomarker
measurement and translation into clinical practice depends on
our ability to make accurate measurements of potential
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